Different pharmaceutical products need similar terminology

AAPS Journal

Volumn 16, Issue 1, 2014, Pages 11-14

  Crommelin, Daan J A ^a   De Vlieger, Jon S B ^b   Weinstein, Vera ^c   Mühlebach, Stefan ^d   Shah, Vinod P ^e   Schellekens, Huub ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b LYGATURE   (Netherlands)

^c TEVA PHARMACEUTICALS   (Israel)

^d Vifor (International) Inc   (Switzerland)

^e Pharmaceutical Consultant   (United States)

Author keywords

Biosimilars; Generics; Non biological complex drugs; Substitution; Terminology

Indexed keywords

BIOLOGICAL PRODUCT; BIOSIMILAR AGENT; GENERIC DRUG; LIPOSOME;

ARTICLE; BIOEQUIVALENCE; CONSENSUS DEVELOPMENT; DRUG LEGISLATION; DRUG MANUFACTURE; DRUG NOMENCLATURE; FOOD AND DRUG ADMINISTRATION; GOVERNMENT REGULATION; PRACTICE GUIDELINE; STANDARDIZATION; WORLD HEALTH ORGANIZATION;

BIOLOGICAL PRODUCTS; DRUGS, GENERIC; TERMINOLOGY AS TOPIC;

EID: 84893082014     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-013-9532-0     Document Type: Article

References (14)

1. FDA, Drug Price Competition and Patent Term Restoration Act of 1984 PL 98-417 (Sept. 24, 1984) Available via htpp://www.fda.gov Accessed 3 Dec 2012.
2. Schellekens H, Klinger E, Mühlebach S, Brin JF, Storm G, Crommelin DJA. The therapeutic equivalence of complex drugs. Regul Toxicol Pharmacol. 2011;59:176-83.
3. Directive 2001/83/EC, http://www.emea.europa.eu/docs/en-GB/document- library/Regulatory-and-procedural-guideline/2009/10/WC500004481.pdf. Accessed 3 Dec 2012.
4. Weise M, Bielsky MC, De Smet K, Ehmann F, Ekman N, Narayanan G, et al. Biosimilars-why terminology matters. Nat Biotechnol. 2011;29(8):690-3.
5. Directive 2010/84/EU, http://ec.europa.eu/health/files/eudralex/vol-1/ dir-2010-84/dir-2010-84-en.pdf. Accessed 3 Dec 2012.
6. The Biologics Price Competition and Innovation Act, BPCI act. 2009. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/ ucm216146.pdf. Accessed 3 Dec 2012.
7. FDA. 2012. Scientific considerations in demonstrating biosimilarity to a reference product http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf. Accessed 3 Dec 2012.
8. FDA. 2012. Quality considerations in demonstrating biosimilarity to a reference protein product http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM291134.pdf. Accessed 3 Dec 2012.
9. FDA. 2012. Biosimilars: questions and answers regarding implementation of the BPCI act http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM273001.pdf. Accessed 3 Dec 2012.
10. Chow SC, Endrenyi L, Lachenbruch PA, Yang LY, Chi E. Scientific factors for assessing biosimilarity and drug interchangeability of follow-on biologics. Biosimilars. 2011;1:13-26.
11. Konski AT. Generic biologics, a comparative analysis of regulatory review. Bio Process Int. 2011;9:34-40.
12. WHO 2009. Guidelines on evaluation of similar biotherapeutic products (SBPs). http://www.who.int/biologicals/areas/biological-therapeutics/ BIOTHERAPEUTICS-FOR-WEB-22APRIL2010.pdf. Accessed 3 Dec 2012.
13. Ehmann F, Saka-Kato K, Duncan R, Hernan Perez de la Ossa D, Pita R, Vidal J-M, et al. Next generation nanomedicines and nanosimilars: EU regulators' initiatives relating to the development and evaluation of nanomedicines. Nanomedicine. 2013;8:849-56.
14. Borchard G, Flühmann B, Mühlebach S. Nanoparticle iron medicinal products-requirements for approval of intended copies of non-biological complex drugs (NBCD) and the importance of clinical comparative studies. Reg Tox Pharm. 2012;64:324-8.